1. Home
  2. RLAY vs ABCL Comparison

RLAY vs ABCL Comparison

Compare RLAY & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Relay Therapeutics Inc.

RLAY

Relay Therapeutics Inc.

HOLD

Current Price

$19.35

Market Cap

4.1B

Sector

Health Care

ML Signal

HOLD

Logo AbCellera Biologics Inc.

ABCL

AbCellera Biologics Inc.

HOLD

Current Price

$12.65

Market Cap

3.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RLAY
ABCL
Founded
2015
2012
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.1B
3.5B
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
RLAY
ABCL
Price
$19.35
$12.65
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
5
Target Price
$19.50
$8.40
AVG Volume (30 Days)
2.8M
4.4M
Earning Date
05-05-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
31.78
10.91
EPS
N/A
N/A
Revenue
$15,355,000.00
$75,128,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$324.03
$21.85
P/E Ratio
N/A
N/A
Revenue Growth
53.44
160.56
52 Week Low
$4.32
$2.75
52 Week High
$21.27
$13.18

Technical Indicators

Market Signals
Indicator
RLAY
ABCL
Relative Strength Index (RSI) 42.46 65.43
Support Level $18.03 $10.38
Resistance Level $20.82 N/A
Average True Range (ATR) 0.69 0.59
MACD -0.06 -0.00
Stochastic Oscillator 20.12 79.02

Price Performance

Historical Comparison
RLAY
ABCL

About RLAY Relay Therapeutics Inc.

Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

Share on Social Networks: